monovalent, bivalent
Showing 1 - 25 of 307
Covid19 Trial in Australia (SII B.1.351, SII Bivalent, SII B.1.617.2)
Withdrawn
- Covid19
- SII B.1.351
- +2 more
-
Maroubra, New South Wales, Australia
- +3 more
May 25, 2022
SARS-CoV-2 Trial (CV0701 Bivalent High dose, CV0701 Bivalent Medium dose, CV0701 Bivalent Low dose)
Not yet recruiting
- SARS-CoV-2
- CV0701 Bivalent High dose
- +4 more
- (no location specified)
Jul 24, 2023
COVID-19 Trial in Melbourne (Tozinameran, Elasomeran, Bivalent Pfizer-BioNTech)
Not yet recruiting
- COVID-19
- Tozinameran
- +3 more
-
Melbourne, Victoria, AustraliaRoyal Children's Hospital, Murdoch Children's Research Institute
Sep 14, 2022
Poliomyelitis Trial in Dhaka (Novel oral poliomyelitis vaccine type 1 (nOPV1), Novel oral poliomyelitis vaccine type 2 (nOPV2),
Not yet recruiting
- Poliomyelitis
- Novel oral poliomyelitis vaccine type 1 (nOPV1)
- +3 more
-
Dhaka, BangladeshInternational Centre for Diarrhoeal Disease Research
Nov 14, 2023
Poliomyelitis Trial in David, Panamá (nOPV2 (monovalent oral polio vaccine))
Completed
- Poliomyelitis
- nOPV2 (monovalent oral polio vaccine)
-
David, Chiriquí, Panama
- +1 more
Jan 20, 2022
COVID-19 Trial in Worldwide (SARS-CoV-2 recombinant protein vaccine Phase 2 Formulation 1, SARS-CoV-2 recombinant protein
Active, not recruiting
- COVID-19
- SARS-CoV-2 recombinant protein vaccine Phase 2 Formulation 1
- +10 more
-
Birmingham, Alabama
- +71 more
Jul 11, 2022
Norovirus Infection Trial in Cleveland (VXA-G1.1-NN, VXA-G2.4-NS, Placebo Tablets)
Completed
- Norovirus Infection
- VXA-G1.1-NN
- +2 more
-
Cleveland, OhioRapid Medical Research
Apr 23, 2021
COVID-19 Trial in Worldwide (SARS-CoV-2 adjuvanted recombinant protein vaccine (monovalent), SARS-CoV-2 adjuvanted recombinant
Active, not recruiting
- COVID-19
- SARS-CoV-2 adjuvanted recombinant protein vaccine (monovalent)
- +2 more
-
Birmingham, Alabama
- +93 more
Jul 22, 2022
COVID-19 Trial in United States (NVX-CoV2373 (5µg), NVX-CoV2601 (5µg), NVX-CoV2601(5µg))
Not yet recruiting
- COVID-19
- NVX-CoV2373 (5μg)
- +6 more
-
Birmingham, Alabama
- +47 more
Jul 2, 2023
COVID-19 Trial (NVX-CoV2601 co-formulated Omicron XBB.1.5 SARS-CoV-2 rS vaccine, Prototype/XBB.1.5 Bivalent Vaccine (5 µg))
Not yet recruiting
- COVID-19
- NVX-CoV2601 co-formulated Omicron XBB.1.5 SARS-CoV-2 rS vaccine
- Prototype/XBB.1.5 Bivalent Vaccine (5 µg)
- (no location specified)
Aug 4, 2023
COVID-19 Trial in Melbourne (Bivalent Moderna, Novavax)
Not yet recruiting
- COVID-19
- Bivalent Moderna
- Novavax
-
Melbourne, Victoria, AustraliaRoyal Children's Hospital, Murdoch Children's Research Institute
Jan 23, 2023
Poliomyelitis Trial in Dhaka (mOPV1, bOPV, fIPV)
Completed
- Poliomyelitis
- mOPV1
- +2 more
-
Dhaka, Bangladeshicddr,b study clinics (Mirpur and CTU Dhaka)
Feb 18, 2021
Norovirus Infections Trial in New Zealand, United States (Open label Bivalent GII.4/GI.1 high dose vaccine 2×10 to the power 11
Recruiting
- Norovirus Infections
- Open label Bivalent GII.4/GI.1 high dose vaccine 2×10 to the power 11 IU/dose
- +3 more
-
La Mesa, California
- +12 more
Jan 12, 2023
Vaccine Reaction Trial in Dhaka (Oral Polio Vaccine, Oral Cholera Vaccine)
Recruiting
- Vaccine Reaction
- Oral Polio Vaccine
- Oral Cholera Vaccine
-
Dhaka, BangladeshHazaribagh Field Clinic
Mar 30, 2022
COVID-19 Trial in Kunming (RQ3013, RQ3025, RQ3027)
Recruiting
- COVID-19
- RQ3013
- +2 more
-
Kunming, Yunnan, ChinaThe Affiliated Hospital of Yunnan University
Jun 22, 2023
COVID-19 Pandemic, Immunogenicity, SARS CoV 2 Infection Trial in Ramat-Gan (mRNA-1273.214 Vaccine, MRNA-1273 Vaccine, Placebo)
Recruiting
- COVID-19 Pandemic
- +3 more
- mRNA-1273.214 Vaccine
- +2 more
-
Ramat-Gan, IsraelSheba Medical Center
Oct 26, 2022
Two Domestic HPV Vaccines and Imported HPV Vaccines in Women
Not yet recruiting
- HPV Infection
- +2 more
- Follow up
-
Fuzhou, Fujian, ChinaFujian Maternity and Child Health Hospital
Nov 16, 2023
Safety of a Single Dose of COMVIGEN Vaccine, Reactogenicity of a Single Dose of COMVIGEN Vaccine, Immunogenicity of a Single
Not yet recruiting
- Safety of a Single Dose of COMVIGEN Vaccine
- +5 more
- Comvigen (Bivalent, ChulaCov19 BNA159.2)
- BIVALENT Pfizer/BNT vaccine
-
Bangkok, Thailand
- +1 more
Jun 29, 2023
Polio Trial in Antwerpen (IMOVAX Inactivated Poliomyelitis Vaccine (IPV), dmLT (adjuvant), Bivalent oral polio vaccine (bOPV))
Completed
- Polio
- Inactivated Poliomyelitis Vaccine (IPV)
- +2 more
-
Antwerpen, Wilrijk, BelgiumUniversity of Antwerpen
Apr 5, 2022
SARS-CoV-2 Infection, COVID-19 Trial (BNT162b5 Bivalent or BNT162b2 Bivalent 30 µg, BNT162b4 5 µg, BNT162b4 10 µg)
Not yet recruiting
- SARS-CoV-2 Infection
- COVID-19
- BNT162b5 Bivalent or BNT162b2 Bivalent 30 µg
- +3 more
- (no location specified)
Sep 14, 2022
Influenza, Human, COVID-19 Trial in United States (bivalent BNT162b2 (original/Omi BA.4/BA.5), qIRV (22/23), QIV)
Recruiting
- Influenza, Human
- COVID-19
- bivalent BNT162b2 (original/Omi BA.4/BA.5)
- +2 more
-
Athens, Alabama
- +18 more
Dec 22, 2022
Ebola Sudan Virus Disease Trial in Siaya, Kampala (cAD3-Sudan Ebolavirus Vaccine, Placebo)
Not yet recruiting
- Ebola Sudan Virus Disease
- cAD3-Sudan Ebolavirus Vaccine
- Placebo
-
Siaya, Kenya
- +1 more
Sep 7, 2023
Booster Dose of Comirnaty in Children Ages 6 Months Though 4
Not yet recruiting
- SARS-CoV-2
- COVID-19
- COMIRNATY intramuscular injection
-
Tokyo, JapanPfizer Local Country
Nov 8, 2023
Lyme Disease Trial in United States (mRNA-1975, mRNA-1982, Placebo)
Recruiting
- Lyme Disease
- mRNA-1975
- +2 more
-
Milford, Connecticut
- +19 more
Jul 26, 2023
Neuroblastoma, High-risk Neuroblastoma, Metastatic Neuroblastoma Trial in United States (OPT-821 (QS-21), oral ß-glucan)
Recruiting
- Neuroblastoma
- +2 more
- OPT-821 (QS-21)
- oral β-glucan
-
Basking Ridge, New Jersey
- +6 more
Sep 21, 2023